Current concepts and perspectives of immunosuppression in organ transplantation

被引:32
|
作者
Scherer, Marcus N.
Banas, Bernhard
Mantouvalou, Kiriaki
Schnitzbauer, Andreas
Obed, Aiman
Kraemer, Bernhard K.
Schlitt, Hans J.
机构
[1] Klinikum Univ Regensburg, Klin & Poliklin Chirurg & Transplantat, D-93042 Regensburg, Germany
[2] Klinikum Univ Regensburg, Klin & Poliklin Innere Med 2, D-93042 Regensburg, Germany
关键词
individually tailored immunosuppression; drug-related side effects; calcineurin-inhibitor-sparing; steroid-avoidance; mTOR inhibitor; impaired renal function; de-novo/recurrence of cancer; true/prope tolerance;
D O I
10.1007/s00423-007-0188-z
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background While early surgical success made organ transplantation possible in the 1950s and 1960s, the breakthrough in clinical organ transplantation was achieved through the discovery and invention of modern immunosuppressive agents in the early/mid-1980s. Especially during the 1990s, a large array of immunosuppressants has expanded the armamentarium used to prevent and treat allograft rejection, resulting in an excellent short-term and an acceptable long-term outcome. However, these drugs have potent but still non-specific immunosuppressive properties and frequently show severe acute and chronic side effects, sometimes questioning the overall success. Concepts/Trends As the "Holy-Grail" of the transplant community, the induction of "true donor-specific tolerance" has not been achieved yet; current immunosuppressive strategies, in particular in Europe, include "individually tailored immunosuppressive" protocols, mostly based on specific immunologic and non-immunologic risk factors. These protocols allow for optimal immunosuppressive protocols for each patient group according to their needs by choosing the most suitable, well-tolerated combination of agents and the most effective doses to avoid acute rejection episodes (incidence and severity) and minimise drug-related toxicity to reduce long-term drug-related morbidity and mortality. Nevertheless, transplant recipient are still being forced to take a life-long course of chemical immunosuppressive agents to keep their graft, knowing about the possible life-threatening side effects. Summary We review current trends of immunosuppressive protocols in liver and kidney transplantation, focusing on calcineurin-inhibitor-sparing protocols, mammalian-target-of-rapamycin (mTOR) inhibitor based-protocols and corticosteroid-avoidance protocols, being aware of the fact, that most of these strategies could be applicable for other transplanted organs, too. Finally, we describe future trends and new developments that are rising on the horizon.
引用
收藏
页码:511 / 523
页数:13
相关论文
共 50 条
  • [21] Ethical challenges of organ transplantation: Current debates and international perspectives
    Wall, Anji E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (11) : 2698 - 2698
  • [22] Ethical Challenges of Organ Transplantation: Current Debates and International Perspectives
    Rimon-Zarfaty, Nitzan
    JOURNAL OF BIOETHICAL INQUIRY, 2024, 21 (03) : 571 - 573
  • [23] Immunosuppression after organ transplantation: Essentials
    Franke, Frederike
    Renders, Lutz
    Linecker, Michael
    Braun, Felix
    TRANSFUSIONSMEDIZIN, 2022, 12 (04) : 233 - 246
  • [24] IMMUNOSUPPRESSION AND CLINICAL ORGAN-TRANSPLANTATION
    CALNE, RY
    TRANSPLANTATION PROCEEDINGS, 1974, 6 (04) : 49 - 51
  • [25] An Overview of Immunosuppression in Solid Organ Transplantation
    Enderby, Cher
    Keller, Cesar A.
    AMERICAN JOURNAL OF MANAGED CARE, 2015, 21 (01): : S12 - S23
  • [26] Payment for immunosuppression after organ transplantation
    Kasiske, BL
    Cohen, D
    Lucey, MR
    Neylan, JF
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (18): : 2445 - 2450
  • [27] Update: Immunosuppression during Organ Transplantation
    Kniepeiss, Daniela
    Rosenkranz, Alexander R.
    Fickert, Peter
    Schemmer, Peter
    TRANSFUSIONSMEDIZIN, 2020, 10 (04) : 221 - 231
  • [28] IMMUNOSUPPRESSION FOR SOLID-ORGAN TRANSPLANTATION
    SHAEFER, MS
    COLLIER, DS
    DIALYSIS & TRANSPLANTATION, 1993, 22 (09) : 542 - &
  • [29] Current Concepts in the Diagnosis and Management of Pneumocystis Pneumonia in Solid Organ Transplantation
    Trubin, Paul A.
    Azar, Marwan M.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2023, 37 (03) : 617 - 640
  • [30] PERSPECTIVES IN ORGAN TRANSPLANTATION
    STARZL, TE
    GROTH, CG
    BRETTSCHNEIDER, L
    SMITH, GV
    PENN, I
    KASHIWAGI, N
    ANTIBIOTICA ET CHEMOTHERAPIA, 1969, 15 : 349 - +